Stock News•3 weeks ago
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
Amneal's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
MarketLens
Is Zai Lab's "Dual-Engine Strategy" Driving Global Growth
4 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•1 months ago
Zai Lab Q2 Earnings Call Highlights
Zai Lab's Q2 net product revenue rose 11% sequentially to $105.8 million, as the company continues investing in a pipeline aimed at transitioning into a global biopharmaceutical business.
Stock News•1 months ago
Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts
Hutchmed's oncology franchise growth, Fruzaqla international rollout, and improving China execution could boost recurring revenues. Late-stage immunology assets and pipeline options like Sovleplenib a...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•45 minutes ago
Prediction: Sept. 10 Will Be a Big Day for Nvidia Shareholders.
Stock News•2 hours ago
QQQ vs QQQM: Same Index, Same Stocks, Different Fee – and the Math Says One Leaves You Thousands Richer
Stock News•2 hours ago
Qualcomm CFO on Amazon AI Deal, Data Center Strategy
Stock News•3 hours ago
Meta Targets Mass Market Automation With New Muse AI Agent
Stock News•3 hours ago